Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial work and R&D pipeline. The conglomerate’s investment—which collectively ...
Dr. Joel Braunstein, CEO of C2N, says, “Samsung is an international leader and widely recognized for the seriousness and thorough reviews it undertakes in its strategic decisions. We greatly ...
ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today announced a $10 million USD investment from Samsung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results